Twenty-one percent of women reported having been told by their doctor or health provider that they had osteoporosis; 19% said they were told they had osteopenia. When asked to rate their own risk of getting osteoporosis compared with women their own

age, 33% rated their risk as lower and 19% as higher. Table 5 Subjects’ awareness of osteoporosis   Percent Concern about osteoporosis  Very concerned 25  Somewhat concerned 54 Talked with their doctor about osteoporosis 43 Doctor told subject she had osteoporosis 21 Doctor told subject she had osteopenia 19 Self-rated risk of learn more osteoporosis  Lower 33  Higher 19 Discussion GLOW is designed to provide an international perspective on fracture risk in women, patient management practices,

patient awareness, physical and emotional function following fracture, application of risk find more assessment models, and functional outcomes following fracture. Previous cohort studies of osteoporosis were designed primarily to identify factors associated with fracture incidence and document the distribution of low bone mineral density and its association with fracture risk. These efforts have been limited to specific regions or areas. GLOW will provide the first description of patterns of risk from an international perspective. Further, the data from GLOW will be used to assess not only fracture risk and incidence, but will identify patient concern and awareness and clinical management at a time Olopatadine when significant efforts have been made to implement treatment guidelines and educate patients about osteoporosis and fracture risk. In these baseline results, a www.selleckchem.com/products/mm-102.html minority of GLOW subjects (43%), among women 55 years and

older, indicated having discussed osteoporosis with their physician in the past year, yet 79% of women in the study were somewhat or very concerned about osteoporosis. Future analyses of GLOW data will examine the link between perceived risk, concern, and physician encounters on treatment risk of fracture and quality of life. Prior studies have reported undertreatment and underdiagnosis of osteoporosis [22]. However, since these studies were conducted, many new therapies have become more widely used than in the past. GLOW will report on contemporary treatment prevalence according to fracture risk and self-reported diagnosis of osteoporosis at a time when a wider range of patient management options have been generally accepted and are available Previously collected risk factor data form the basis for risk-scoring algorithms designed to predict fracture risk and aid physicians in targeting treatment to those most in need [23–26]. GLOW will update data on these factors and allow the calculation of patterns of international fracture risk.